Alven
France
- Paris, Ile de France
- 28/11/2022
- Series B
- $10,000,000
Alven is an independent early-stage venture capital firm with over $500m under management and a successful track record of backing more than 130 startups over 20 years.
Our mission at Alven consists in supporting the long-term success of European category-defining startups with global reach, starting at Series A or Seed stage. Alven’s sectors of interest include notably B2C/B2B marketplaces, productivity and dev tools, vertical AI platforms, consumer social & entertainment, B2C financial services and wellness brands.
Examples of past or current investments
PRODUCTIVITY SOFTWARE:
Akeneo - Bime Analytics - Dataiku - Georges.tech - People Doc - Qonto - Webhelp
DEV TOOLS:
Algolia - Entropysoft - Platform.sh - Sqreen - Stripe - Wit.ai
VERTICAL AI PLATFORMS:
Cardiologs - Clustree - Scortex - Tinyclues - XWing
B2B MARKETPLACES:
Ankorstore - Companeo - Jobteaser - Meero
SOCIAL & ENTERTAINMENT:
Happn - Madbox - Tonsser - Yubo
B2C FINANCIAL SERVICES:
MeilleursAgents - Pretto - The Guarantors - Virgil
B2C MARKETPLACES:
Captain Train - Drivy - Heetch - Liligo - Marco Vasco - OpenClassrooms - SeLoger - Smallable
WELLNESS BRANDS:
Birchbox - Feed. - Joone - Sézane - Typology
Pitch your start-up via www.alven.co
https://twitter.com/alvencap
- Industry Venture Capital and Private Equity Principals
- Website https://alven.co/
- LinkedIn https://www.linkedin.com/company/alven-vc/?originalSubdomain=fr
Atlas Invest | $25,000,000 | (Jan 22, 2026)
AiStrike | $7,000,000 | (Jan 22, 2026)
Zarminali Pediatrics | $110,000,000 | (Jan 22, 2026)
Statusphere | $18,000,000 | (Jan 21, 2026)
Think Bioscience | $55,000,000 | (Jan 21, 2026)
ErVimmune | $19,917,795 | (Jan 21, 2026)
Formulary Financial | $4,600,000 | (Jan 21, 2026)
Ultra Pouches | $11,000,000 | (Jan 21, 2026)
XBuild | $19,000,000 | (Jan 21, 2026)
Infinitopes | $15,400,000 | (Jan 21, 2026)